PTC Therapeutics (PTCT) News Today $47.49 -1.12 (-2.30%) (As of 01:08 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd trimmed its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 57.0% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,829 shares of the biopharmaceutical company's stockDecember 16 at 4:12 AM | marketbeat.comState Street Corp Increases Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)State Street Corp raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,899,040 shares of the biopharmaceutical company'sDecember 16 at 3:49 AM | marketbeat.comPTC Therapeutics (PTCT) Receives a Buy from RBC CapitalDecember 13, 2024 | markets.businessinsider.comPTC Therapeutics (NASDAQ:PTCT) Upgraded to "Overweight" at Morgan StanleyMorgan Stanley upgraded PTC Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the stock from $45.00 to $67.00 in a research note on Friday.December 13, 2024 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 12.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 133,977 shaDecember 12, 2024 | marketbeat.comCantor Fitzgerald says ‘aggressively’ buy uniQure, PTC TherapeuticsDecember 11, 2024 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Purchased by Two Sigma Advisers LPTwo Sigma Advisers LP raised its position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 10.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 429,842 shares of the biopharmaceutical company's stock after purchasing an additional 40,300 sharesDecember 9, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Fmr LLCFmr LLC lowered its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 4.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,057,182 shares of the biopharmaceutical company's stock aDecember 9, 2024 | marketbeat.comAnalysts Set PTC Therapeutics, Inc. (NASDAQ:PTCT) Target Price at $51.15December 9, 2024 | americanbankingnews.comWellington Management Group LLP Cuts Stake in PTC Therapeutics, Inc. (NASDAQ:PTCT)Wellington Management Group LLP reduced its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 3.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 7,892,799 shares of the biopharmaDecember 8, 2024 | marketbeat.comBNP Paribas Financial Markets Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)BNP Paribas Financial Markets cut its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 42.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 72,946 shares of the bioDecember 7, 2024 | marketbeat.comLeerink Partnrs Has Negative Outlook of PTCT FY2024 EarningsDecember 7, 2024 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down After Insider SellingDecember 7, 2024 | americanbankingnews.comPTC Therapeutics: Hold Rating Amid Strategic Collaboration with Novartis and Clinical UncertaintiesDecember 6, 2024 | markets.businessinsider.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by Janus Henderson Group PLCJanus Henderson Group PLC lowered its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 37.3% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,870,217 shares of the biopharmaceutical company's stock after selling 1,111,342 shares duDecember 6, 2024 | marketbeat.comInsider Selling: PTC Therapeutics, Inc. (NASDAQ:PTCT) CAO Sells 17,800 Shares of StockDecember 5, 2024 | insidertrades.comPTC Therapeutics price target raised to $32 from $26 at CitiDecember 5, 2024 | markets.businessinsider.comCharles Schwab Investment Management Inc. Acquires 47,902 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)Charles Schwab Investment Management Inc. boosted its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 7.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 706,730 shares of the biopharmaceuticalDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Takes $7.23 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Parkman Healthcare Partners LLC bought a new position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 195,000 shares of the biopharmaceutical company's stock, valued at approximaDecember 4, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Lowers Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Jacobs Levy Equity Management Inc. reduced its stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 13.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,486,297 shares of the biopharmaceutDecember 4, 2024 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Recommendation of "Hold" from AnalystsPTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen research firms that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, seven have gDecember 4, 2024 | marketbeat.comPTC Therapeutics price target raised to $41 from $31 at BofADecember 3, 2024 | msn.comBarclays Keeps Their Hold Rating on PTC Therapeutics (PTCT)December 3, 2024 | markets.businessinsider.comPTC Therapeutics price target raised to $71 from $47 at UBSDecember 3, 2024 | markets.businessinsider.comPTC Therapeutics Stock Eyes Further Rally After Price-Target Hikes On Huntington’s Therapy Deal With Novartis: Retail Buzz GrowsDecember 3, 2024 | msn.comPoint72 Hong Kong Ltd Has $423,000 Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Point72 Hong Kong Ltd lessened its holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 80.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,402 shares of the biopharmaceutical company's stock afterDecember 3, 2024 | marketbeat.comPTC Therapeutics enters global license, collaboration agreement with NovartisDecember 2, 2024 | markets.businessinsider.comHold Recommendation for PTC Therapeutics: Balancing Promising Prospects with Regulatory and Competitive ChallengesDecember 2, 2024 | markets.businessinsider.comPTC Therapeutics Scores A $2.9 Billion Novartis Deal And Tops Profit-Taking ZoneDecember 2, 2024 | msn.comPTC Therapeutics Stock Soars on Novartis Licensing AgreementDecember 2, 2024 | investopedia.comPTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's ProgramDecember 2, 2024 | benzinga.comPTC Inks License And Collaboration Deal With Novartis For PTC518 Huntington's Disease ProgramDecember 2, 2024 | markets.businessinsider.comNovartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14%December 2, 2024 | finance.yahoo.comPTC Therapeutics stock jumps on $2.9B license deal with Novartis for Huntington's disease drug candidateDecember 2, 2024 | msn.comPTC Therapeutics signs up to $1.9 billion licensing deal with NovartisDecember 2, 2024 | reuters.comPTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease ProgramDecember 2, 2024 | prnewswire.comThrivent Financial for Lutherans Buys Shares of 39,098 PTC Therapeutics, Inc. (NASDAQ:PTCT)Thrivent Financial for Lutherans acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 39,098 shares of the biopharmaceuticalDecember 1, 2024 | marketbeat.comIntech Investment Management LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Intech Investment Management LLC bought a new position in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm bought 18,806 shares of the biopharmaceutical company's stock, valued at approximately $698,000. A number ofNovember 30, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Stock Price Down 3.4% - Here's WhyPTC Therapeutics (NASDAQ:PTCT) Stock Price Down 3.4% - What's Next?November 29, 2024 | marketbeat.comPTC Therapeutics, Inc.: PTC Therapeutics Announces Topline Results of CardinALS Trial of Utreloxastat in ALS PatientsNovember 28, 2024 | finanznachrichten.deMassachusetts Financial Services Co. MA Takes $1.66 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)Massachusetts Financial Services Co. MA acquired a new stake in PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 44,771 shares of the biopNovember 28, 2024 | marketbeat.comTD Cowen Remains a Hold on PTC Therapeutics (PTCT)November 28, 2024 | markets.businessinsider.comPTC Therapeutics (NASDAQ:PTCT) Given New $52.00 Price Target at Robert W. BairdRobert W. Baird raised their price objective on PTC Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research note on Wednesday.November 27, 2024 | marketbeat.comPTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 MillionNovember 27, 2024 | prnewswire.comConnor Clark & Lunn Investment Management Ltd. Has $1.44 Million Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)Connor Clark & Lunn Investment Management Ltd. decreased its holdings in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 28.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,910 shares oNovember 27, 2024 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month High Following Analyst UpgradePTC Therapeutics (NASDAQ:PTCT) Hits New 52-Week High Following Analyst UpgradeNovember 27, 2024 | marketbeat.comPTC's utreloxastat fails Phase 2 clinical study for ALSNovember 26, 2024 | msn.comPTC Therapeutics: Growth Potential Amid Strategic Shifts and Upcoming CatalystsNovember 26, 2024 | markets.businessinsider.comPTC Therapeutics: Phase 2 CardinALS study did not meet its primary endpointNovember 26, 2024 | markets.businessinsider.comPTC Therapeutics to End Development of ALS TreatmentNovember 26, 2024 | marketwatch.com Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Healthcare Takes A Big Step Forward With The Help of A.I. (Ad)To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare. Click here to learn more about the booming eHealth industry - and see which microcap will be at the PTCT Media Mentions By Week PTCT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTCT News Sentiment▼1.230.80▲Average Medical News Sentiment PTCT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTCT Articles This Week▼86▲PTCT Articles Average Week Get PTC Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SMMT News GMAB News RDY News SRPT News CTLT News PCVX News QGEN News ITCI News ROIV News ASND News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTCT) was last updated on 12/17/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PTC Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTCT Stock Alerts